BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 10530403)

  • 1. Subpopulations of human granulosa-luteal cells obtained from gonadotropin- or gonadotropin-releasing hormone agonist/gonadotropin-treated follicles in in vitro fertilization-embryo transfer cycles.
    Gersak K; Tomazevic T
    J Assist Reprod Genet; 1999 Oct; 16(9):488-91. PubMed ID: 10530403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of follicular phase duration on human granulosa-luteal cell subpopulations in natural and stimulated IVF-ET cycles.
    Gersak K; Tomazevic T
    J Assist Reprod Genet; 1995 Oct; 12(9):650-6. PubMed ID: 8580666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subpopulations of human granulosa-luteal cells in natural and stimulated in vitro fertilization-embryo transfer cycles.
    Gersak K; Tomazevic T
    Fertil Steril; 1996 Mar; 65(3):608-13. PubMed ID: 8774296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.
    Penzias AS; Shamma FN; Gutmann JN; Seifer DB; DeCherney AH; Lavy G
    J Assist Reprod Genet; 1992 Jun; 9(3):244-7. PubMed ID: 1525454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subpopulations of human granulosa-luteal cells obtained during early timed and during normally timed follicular aspiration in in-vitro fertilization-embryo transfer cycles.
    Gersak K; Tomazevic T; Meden-Vrtovec H
    Fertil Steril; 1997 Dec; 68(6):1093-6. PubMed ID: 9418703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?
    Lin Y; Kahn JA; Hillensjö T
    Hum Reprod; 1999 Apr; 14(4):885-8. PubMed ID: 10221213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH agonist treatment of luteal phase deficiency in HCG-triggered IVF cycles: a matched case-control study.
    Mendoza-Tesarik R; Mendoza N; López CC; Tesarik J
    Reprod Biomed Online; 2019 Aug; 39(2):225-230. PubMed ID: 31178369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteal phase consequences of low-dose gonadotropin-releasing hormone agonist therapy in nonluteal-supported in vitro fertilization cycles.
    Long CA; Sopelak VM; Lincoln SR; Cowan BD
    Fertil Steril; 1995 Sep; 64(3):573-6. PubMed ID: 7641913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of luteal phase ovulation induction and ultra-short gonadotropin-releasing hormone agonist protocols in older patients undergoing in vitro fertilization.
    Wang T; Sun Z; Lim JP; Yu Y
    Libyan J Med; 2019 Dec; 14(1):1597327. PubMed ID: 30935302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated GnRH agonist doses for luteal support: a proof of concept.
    Wiser A; Klement AH; Shavit T; Berkovitz A; Koren RR; Gonen O; Amichay K; Shulman A
    Reprod Biomed Online; 2019 Nov; 39(5):770-776. PubMed ID: 31628035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
    Albano C; Smitz J; Tournaye H; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
    Hum Reprod; 1999 Jun; 14(6):1426-30. PubMed ID: 10357952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of HCG in IVF Treatment: Does it depend on age or on protocol?
    Theofanakis C; Athanasiou V; Liokari E; Stavrou S; Sakellariou M; Athanassiou AI; Athanassiou A; Drakakis P; Loutradis D
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):341-345. PubMed ID: 30794953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
    Norman RJ; Warnes GM; Wang X; Kirby CA; Matthews CD
    Hum Reprod; 1991 Feb; 6(2):206-13. PubMed ID: 1905309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone.
    Claman P; Domingo M; Leader A
    Hum Reprod; 1992 Apr; 7(4):487-9. PubMed ID: 1522190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-dose versus single-dose gonadotropin-releasing hormone agonist after first in vitro fertilization failure associated with luteal phase deficiency: A randomized controlled trial.
    Qu D; Li Y
    J Int Med Res; 2020 Jun; 48(6):300060520926026. PubMed ID: 32495663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial.
    Mochtar MH; Hogerzeil HV; Mol BW
    Hum Reprod; 1996 Aug; 11(8):1602-5. PubMed ID: 8921100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.